Risk factor
High price volatility
Profitability factor
Greatly undervalued vs peers
About
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, underpriced
Target Price
The average target price of ZEAL.CO is 758 and suggests 48% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell